Recent News

• 11.18.2025 - Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation
• 11.14.2025 - Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test
• 10.27.2025 - Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth
• 09.02.2025 - Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
• 09.02.2025 - Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
• 08.21.2025 - Trinity Biotech Appoints Paul Tivnan as Non-Executive Director
• 08.20.2025 - Regulatory Approval Granted for Commencement Of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation
• 08.20.2025 - Regulatory Approval Granted for Commencement of Trinity Biotech’s Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation

Recent Filings

• 11.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.18.2025 - EX-99.1 EX-99.1
• 10.24.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 10.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.23.2025 - EX-99.1 EX-99.1
• 09.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.08.2025 - EX-99.1 EX-99.1
• 09.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.02.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]